Literature DB >> 2360461

Flunarizine treatment in poor-grade aneurysm patients.

S Fujita1, T Kawaguchi, Y Shose, S Urui.   

Abstract

A cerebral Ca2+ overload blocker--flunarizine hydrochloride--was used with excellent results for prophylaxis of delayed ischaemic neurological deficit (DIND) in severe subarachnoid haemorrhage. The drug was administered orally at a dose of 10 mg, four times daily for four days, followed by three times daily for three days and twice daily for 14 more days. Of 72 patients treated with flunarizine, only one developed permanent DIND. 37 consecutive patients who were in Fisher's group III and were treated with flunarizine from immediately after early surgery were compared retrospectively with the 37 consecutive Control Group patients, who also belong to Fisher's group III. Among the Control Group patients, eight died from DIND and ten developed infarction from DIND, while flunarizine strongly prevented (p less than 0.001) DIND. Furthermore, the only one DIND was attributable to failure of administration of flunarizine. There were no side-effects from flunarizine. The association of severe angiographic vasospasm was less frequent in the Flunarizine Group (18% vs 57%, p less than 0.02). From this evidence, it might be concluded that flunarizine significantly inhibits the occurrence of severe neurological deficit due to delayed vasospasm. This highly beneficial effect on severe delayed vasospasm might be attributable to its intense inhibitory action on intracellular Ca2+ overloads especially in severe pathological situations.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2360461     DOI: 10.1007/bf01420186

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  24 in total

1.  Surgical risk as related to time of intervention in the repair of intracranial aneurysms.

Authors:  W E Hunt; R M Hess
Journal:  J Neurosurg       Date:  1968-01       Impact factor: 5.115

2.  Radical scavenging action of flunarizine in rat brain in vitro.

Authors:  K Kubo; I Yoshitake; Y Kumada; K Shuto; N Nakamizo
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-12

3.  Absorption and tissue distribution of flunarizine in rats, pigs and dogs.

Authors:  M Michiels; R Hendriks; F Knaeps; R Woestenborghs; J Heykants
Journal:  Arzneimittelforschung       Date:  1983

Review 4.  The role of calcium in cell death.

Authors:  J L Farber
Journal:  Life Sci       Date:  1981-09-28       Impact factor: 5.037

Review 5.  Cerebral vasospasm following aneurysmal subarachnoid hemorrhage.

Authors:  N F Kassell; T Sasaki; A R Colohan; G Nazar
Journal:  Stroke       Date:  1985 Jul-Aug       Impact factor: 7.914

6.  Protection by flunarizine against endothelial cell injury in vivo.

Authors:  J Hladovec; F De Clerck
Journal:  Angiology       Date:  1981-07       Impact factor: 3.619

7.  Selectivity of calcium antagonism and serotonin antagonism with respect to venous and arterial tissues.

Authors:  J M Van Nueten; P M Vanhoutte
Journal:  Angiology       Date:  1981-07       Impact factor: 3.619

8.  Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.

Authors:  G S Allen; H S Ahn; T J Preziosi; R Battye; S C Boone; S C Boone; S N Chou; D L Kelly; B K Weir; R A Crabbe; P J Lavik; S B Rosenbloom; F C Dorsey; C R Ingram; D E Mellits; L A Bertsch; D P Boisvert; M B Hundley; R K Johnson; J A Strom; C R Transou
Journal:  N Engl J Med       Date:  1983-03-17       Impact factor: 91.245

9.  Prevention of vasospasm by early operation with removal of subarachnoid blood.

Authors:  M Mizukami; T Kawase; T Usami; T Tazawa
Journal:  Neurosurgery       Date:  1982-03       Impact factor: 4.654

10.  "Calcium entry blockers" as cerebral protecting agents: comparative activity in tests of hypoxia and hyperexcitability.

Authors:  A Wauquier; D Ashton; G Clincke; J Fransen
Journal:  Jpn J Pharmacol       Date:  1985-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.